SLC5A2 and cardiovascular disorder: In conclusion, we hypothesize that the protective effects of an ongoing SGLT2-i therapy and some advantages in the baseline characteristics such as younger age, slightly better kidney function and lower LDL-Cholesterol level in the SGLT2-i group were counterbalanced and overweighed by severe concomitant cardiovascular diseases and worse glycemic control.